8.1 Manuscript Development, Author Review, and Sponsor Boundaries
Key Takeaways
Manuscript workflows should be defined for the project and venue; an annotated outline can align the author group, but GPP 2022 does not prescribe one universal five-stage process or fixed review duration.
Named authors must direct the intellectual content, critically review the work, approve the version to be published, and accept accountability under the applicable authorship criteria.
Sponsor review can legitimately address scientific accuracy, safety, data consistency, legal or regulatory issues, confidentiality, and intellectual property when agreements and governance preserve author control and timely dissemination.
Commercial preference cannot justify unsupported claims, suppression of unfavorable results, honorary authorship, or indefinite delay.
A patent-review delay should follow the research or publication agreement and be limited and reasonable for the stated purpose; GPP 2022 does not establish a universal 30-, 60-, or 90-day allowance.
Manuscript Development, Author Review, and Sponsor Boundaries
A reliable manuscript process turns verified analyses into a report that authors understand and can defend. It should be structured enough to preserve decisions and versions, but flexible enough for the study, agreement, author group, and target journal. GPP 2022 is principle based; it does not prescribe one mandatory sequence called “AO, AD1, AD2, final,” fixed review periods, or a universal sponsor sign-off gate.
Design the workflow for the project
A common workflow may include a kickoff, source package, outline, drafts, author reviews, data verification, compliance or legal review, final approval, submission, and peer-review revisions. Projects can combine or reorder steps. A brief report may not need a formal annotated outline; a complex primary trial manuscript may benefit greatly from one.
At kickoff, confirm:
- publication objective and evidence to be reported;
- author and contributor roles, contact details, and anticipated availability;
- target venue and reporting guideline;
- source documents, analysis status, and data owners;
- contractual review, confidentiality, and intellectual-property provisions;
- disclosure, acknowledgment, data-sharing, registration, and transparency needs;
- realistic milestones tied to data readiness and venue deadlines;
- document system, version naming, comment resolution, and audit trail.
The schedule should allow meaningful review. A two-week review may be ample for a short abstract and inadequate for a complex manuscript. The right response to a compressed timeline is to define a feasible scope, prioritize critical reviewers, identify risks, and negotiate—not to declare that every outline needs two to three weeks or that silence equals approval.
The annotated outline
An annotated outline can align the team before prose drafting. It may specify the research question, journal structure, main claims, data displays, section logic, reporting-checklist items, and source citations. Authors can correct interpretation early, before polished prose creates anchoring or costly rework.
The outline is not a substitute for later review of the complete manuscript. Approval of headings or bullets does not satisfy final-approval or accountability criteria. If new analyses or interpretations emerge, return them to the authors even if the outline was previously agreed.
Author responsibilities and professional writing support
Every named author must meet the applicable authorship criteria. Under ICMJE, that includes substantial contribution, drafting or critical intellectual revision, final approval, and accountability. A professional writer can organize evidence, draft under author direction, check consistency, manage comments, and support guideline adherence. Ethical writing assistance is disclosed with the writer's name, appropriate credentials or role, affiliation, and funding according to venue requirements.
Writers should not manufacture consensus, decide authorship as a reward, sign author declarations, or conceal sponsor involvement. Authors should have access to the information needed to interpret the work and should not approve text they cannot evaluate.
Legitimate sponsor review
In sponsored research, review is not inherently improper. Depending on the study, contracts, and policies, sponsor functions may check:
- consistency with verified data, protocol, analysis plan, and study report;
- medical and scientific accuracy;
- safety information and pharmacovigilance implications;
- privacy, confidentiality, and data-protection issues;
- intellectual property;
- regulatory or legal accuracy;
- consistency of disclosures and sponsor-role statements;
- operational readiness for submission.
It is too narrow to say sponsor review may address only factual errors and patents. It is also wrong to let a sponsor dictate conclusions, insert unsupported superiority, remove an unfavorable result, select authors for influence, or prevent publication for commercial convenience. Agreements should preserve investigator and author rights and describe review timing, permitted purposes, and dispute handling.
Resolving comments
Classify comments by issue rather than by job title. A statistician may identify a scientific problem; a lawyer may flag an inaccurate legal statement; a commercial colleague may notice a typographical error. Conversely, a senior scientific reviewer may propose an unsupported interpretation. Evaluate each comment against the data, protocol, sources, venue policy, agreement, and ethical standards.
Keep a response log for material comments. Record the proposed change, rationale, evidence, decision, and responsible author or owner. Escalate unresolved scientific interpretation to the author group and unresolved contractual or legal questions to the appropriate specialists. Do not hide a rejected commercial request by deleting it from the record.
Patents, confidentiality, and timing
Premature disclosure can affect patent rights or breach confidentiality. A research or publication agreement may allow a sponsor to review a proposed publication and request a limited delay so a patent application can be filed. The controlling language and applicable law matter. GPP 2022 supports timely dissemination and does not create a universal “30 to 60 days, rarely 90” rule.
The defensible response is to:
- read the actual agreement and publication policy;
- identify the specific protectable information;
- involve appropriate intellectual-property counsel;
- use only the limited, reasonable delay authorized for the legitimate purpose;
- avoid indefinite suppression or delay for sales, launch, or reputational reasons;
- document the request, decision, and revised schedule.
Confidential information that is unrelated to the scientific report may be removed when authorized, but confidentiality labels cannot be used to conceal material methods, results, harms, or limitations needed to understand the work.
Final approval and submission
Before submission, verify the current manuscript, tables, figures, supplement, registry information, reporting checklist, disclosures, acknowledgments, data-sharing statement, and funding statement. Obtain documented approval from every named author for the version to be submitted. Follow the journal's authorship and electronic-signature process; no coordinator may approve or sign for an author.
Peer-review revisions can change interpretation and must return to authors for review. The final version to be published—not merely the original submission—requires author approval under ICMJE. If an author becomes unavailable, consult the journal rather than forging approval or silently changing the byline.
Important
In exam questions, distinguish legitimate, bounded review from control. Preserve author authority, evaluate comments on evidence, follow the actual agreement, document decisions, and keep dissemination timely.
A commercial reviewer asks authors to claim superiority over a comparator although the trial was designed for non-inferiority and does not support that claim. What should the publication professional do?
Reject the unsupported claim, document the resolution, and preserve the authors’ evidence-based interpretation.
Insert it because sponsor reviewers have final editorial authority.
Move it to the abstract where qualifications are unnecessary.
Remove the comparator data and let readers infer superiority.
A patent attorney requests a submission hold for a potentially patentable formulation. Which response is most defensible?
Delay until the patent is granted, regardless of the agreement.
Review the agreement and policy, identify the legitimate patent need, and use only an authorized, limited, reasonable delay while documenting the decision.
Apply a universal 60-day GPP rule without reading the contract.
Refuse every patent-related delay because publication timing always overrides intellectual property.
What is the main value of an annotated outline for a complex manuscript?
It replaces author review of the drafted manuscript.
It serves as the signed final publication approval.
It lets the author group align early on structure, interpretation, data displays, sources, and venue requirements before full prose is developed.
It authorizes commercial teams to reuse preliminary claims.
Sections you finish are checked off in the contents.